Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review
Simple Summary Pancreatic cancer is one of the most aggressive forms of cancer, and in the majority of cases involves a mutation in the RAS gene, a protein which, when activated, stimulates tumour growth. Inhibiting this protein has long been a challenge, and previous drugs were effective against only one rare type of...